Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Rhea-AI Summary
Zhengye Biotechnology (Nasdaq: ZYBT) received a Nasdaq notice on May 29, 2026, that its shares no longer meet the US$1.00 minimum bid price requirement under Rule 5550(a)(2), after trading below that level for 30 consecutive business days.
The company has 180 days, until November 25, 2026, to regain compliance by achieving a closing bid of at least US$1.00 for 10 consecutive business days. The notice does not immediately affect its Nasdaq Capital Market listing or business operations. Zhengye is monitoring its share price and may consider options such as a reverse share split to restore compliance.
Positive
- 180-day compliance period until November 25, 2026
- Nasdaq notice does not immediately affect current listing status
- Business operations reportedly unaffected by bid price deficiency
- Company may use tools such as a reverse share split to regain compliance
Negative
- Shares traded below US$1.00 for 30 consecutive business days
- Non-compliance with Nasdaq Rule 5550(a)(2) minimum bid price
- Risk of potential delisting if compliance not regained by deadline
News Market Reaction – ZYBT
In the Jun 5 session, ZYBT gained 0.06%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Earnings results | Negative | -5.7% | Fiscal 2025 revenue decline and swing from profit to net loss. |
| Apr 06 | Capital structure change | Neutral | +1.2% | Implementation of dual-class share structure after shareholder approval. |
| Feb 10 | Strategic update | Neutral | -2.9% | Chairman’s letter summarizing 2025 milestones and 2026 priorities. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across recent events, ZYBT’s share reactions have generally aligned with the tone of the news, with weak earnings drawing a sharper negative move than governance or strategy updates.
Over the last several months, Zhengye Biotechnology reported weak fiscal 2025 results on Apr 28, 2026, with revenue down and a net loss, and the stock fell 5.69%. Earlier, it implemented a dual-class share structure effective Apr 7, 2026, with a modest 1.23% gain. A Feb 10, 2026 chairman’s letter outlining 2025 milestones and 2026 priorities coincided with a 2.86% decline. The current Nasdaq minimum bid price notice follows this period of operational and governance change alongside share-price pressure.
Key Terms
minimum bid price regulatory
nasdaq capital market regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, announced that the Company had received a written notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on May 29, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules 5550(a)(2) for continued listing on the Nasdaq.
Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US
The Notification Letter does not impact the Company’s listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until November 25, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s Class A ordinary shares must have a closing bid price of at least US
The Company’s business operations are not affected by the receipt of the Notification Letter. The Company is monitoring the closing bid price of its Class A ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding Class A ordinary shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.
About Zhengye Biotechnology Holding Limited
Through Jilin Zhengye Biological Products Co., Ltd., the Company’s operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt as of the date of this press release. The operating entity has three veterinary vaccine production floors (including 13 vaccine production lines), one quality examination center, and one animal facility for vaccine development, all operating in accordance with Good Manufacturing Practices for Veterinary Drugs issued by the Ministry of Agriculture and Rural Affairs of the PRC. For more information, please visit the Company’s website: http://ir.jlzybio.com.
Forward-Looking Statements
This announcement contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the United States Securities and Exchange Commission.
For more information, please contact:
Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
